JP2004532240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532240A5 JP2004532240A5 JP2002586946A JP2002586946A JP2004532240A5 JP 2004532240 A5 JP2004532240 A5 JP 2004532240A5 JP 2002586946 A JP2002586946 A JP 2002586946A JP 2002586946 A JP2002586946 A JP 2002586946A JP 2004532240 A5 JP2004532240 A5 JP 2004532240A5
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydro
- azepine
- benzo
- sulfonyl
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 phenyloxy, benzyloxy Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- UQPAAGMBVLWZTE-UHFFFAOYSA-N n,n-dimethyl-1-[1-(2,3,4,5-tetrahydro-1h-3-benzazepin-7-ylsulfonyl)indol-3-yl]methanamine Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C=C(C4=CC=CC=C43)CN(C)C)=CC=C21 UQPAAGMBVLWZTE-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- NMHWNKKUIRCGIB-UHFFFAOYSA-N 7-(2,3-dihydroindol-1-ylsulfonyl)-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC(S(=O)(N3C4=CC=CC=C4CC3)=O)=CC=C21 NMHWNKKUIRCGIB-UHFFFAOYSA-N 0.000 claims 1
- CHVUYBOCNPVDFI-UHFFFAOYSA-N 7-(4,6-difluoroindol-1-yl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C=CC4=C(F)C=C(C=C43)F)=CC=C21 CHVUYBOCNPVDFI-UHFFFAOYSA-N 0.000 claims 1
- DLYTYTWIXFVGMN-UHFFFAOYSA-N 7-(5,6-difluoroindol-1-yl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C=CC=4C=C(C(=CC=43)F)F)=CC=C21 DLYTYTWIXFVGMN-UHFFFAOYSA-N 0.000 claims 1
- NYXYOLLGVBUDFS-UHFFFAOYSA-N 7-(7-nitroindol-1-yl)sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C=CC=4C=CC=C(C3=4)[N+](=O)[O-])=CC=C21 NYXYOLLGVBUDFS-UHFFFAOYSA-N 0.000 claims 1
- NOYPAXGYMHKKCY-UHFFFAOYSA-N 7-[(5-bromo-2,3-dihydroindol-1-yl)sulfonyl]-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C4=CC=C(C=C4CC3)Br)=CC=C21 NOYPAXGYMHKKCY-UHFFFAOYSA-N 0.000 claims 1
- LUAWNRLPIVPOBE-UHFFFAOYSA-N 7-[6-(trifluoromethyl)indol-1-yl]sulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C=CC4=CC=C(C=C43)C(F)(F)F)=CC=C21 LUAWNRLPIVPOBE-UHFFFAOYSA-N 0.000 claims 1
- KIMKGDISOLCZFN-UHFFFAOYSA-N 7-indol-1-ylsulfonyl-2,3,4,5-tetrahydro-1h-3-benzazepine Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C4=CC=CC=C4C=C3)=CC=C21 KIMKGDISOLCZFN-UHFFFAOYSA-N 0.000 claims 1
- NBHUTSNNBGPXAS-UHFFFAOYSA-N 9-(2,3,4,5-tetrahydro-1h-3-benzazepin-7-ylsulfonyl)-1,2,3,4-tetrahydrocarbazole Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C4=CC=CC=C4C=4CCCCC=43)=CC=C21 NBHUTSNNBGPXAS-UHFFFAOYSA-N 0.000 claims 1
- AQJRPRULCZPQFY-UHFFFAOYSA-N 9-(2,3,4,5-tetrahydro-1h-3-benzazepin-7-ylsulfonyl)carbazole Chemical compound C1CNCCC2=CC(S(=O)(=O)N3C4=CC=CC=C4C4=CC=CC=C43)=CC=C21 AQJRPRULCZPQFY-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0111186.3A GB0111186D0 (en) | 2001-05-08 | 2001-05-08 | Novel compounds |
| PCT/EP2002/004804 WO2002089811A1 (en) | 2001-05-08 | 2002-05-02 | Benzo[d]azepine derivatives as 5-ht6 receptor antagonists. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532240A JP2004532240A (ja) | 2004-10-21 |
| JP2004532240A5 true JP2004532240A5 (enExample) | 2005-12-22 |
Family
ID=9914193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002586946A Pending JP2004532240A (ja) | 2001-05-08 | 2002-05-02 | ５−ｈｔ６受容体アンタゴニストとしてのベンゾ［ｄ］アゼピン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040192671A1 (enExample) |
| EP (1) | EP1392316B1 (enExample) |
| JP (1) | JP2004532240A (enExample) |
| AT (1) | ATE293448T1 (enExample) |
| DE (1) | DE60203797T2 (enExample) |
| ES (1) | ES2238583T3 (enExample) |
| GB (1) | GB0111186D0 (enExample) |
| WO (1) | WO2002089811A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60304695T2 (de) * | 2002-02-13 | 2006-09-21 | Glaxo Group Ltd., Greenford | 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems |
| ATE398108T1 (de) | 2002-03-27 | 2008-07-15 | Glaxo Group Ltd | Chinolinderivate und deren verwendung als 5-ht6 liganden |
| TWI281914B (en) | 2002-05-29 | 2007-06-01 | Glaxo Group Ltd | Compounds |
| HRP20060100T3 (en) | 2003-07-22 | 2007-03-31 | Arena Pharmaceuticals Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
| GB0321475D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| CN101048407A (zh) * | 2004-09-03 | 2007-10-03 | 普莱希科公司 | 双环杂芳基pde4b抑制剂 |
| US9084742B2 (en) | 2007-12-12 | 2015-07-21 | Axovant Sciences Ltd. | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| AU2010262905B2 (en) | 2009-06-17 | 2015-04-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| IN2013DN02552A (enExample) * | 2010-09-01 | 2015-08-07 | Arena Pharm Inc | |
| KR20130138770A (ko) * | 2010-09-01 | 2013-12-19 | 아레나 파마슈티칼스, 인크. | 광학적으로 활성 산을 갖는 로르카세린의 염 |
| EP2611433A2 (en) * | 2010-09-01 | 2013-07-10 | Arena Pharmaceuticals, Inc. | Non-hygroscopic salts of 5-ht2c agonists |
| KR20140014110A (ko) | 2010-12-16 | 2014-02-05 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| EP3255049A1 (en) | 2012-06-29 | 2017-12-13 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| WO2014039831A1 (en) | 2012-09-07 | 2014-03-13 | Takeda Pharmaceutical Company Limited | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES |
| EP3068782B1 (en) | 2013-11-13 | 2018-05-23 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| ES2741444T3 (es) | 2013-11-13 | 2020-02-11 | Vertex Pharma | Inhibidores de la replicación de virus de la gripe |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| JP2018516992A (ja) | 2015-06-12 | 2018-06-28 | アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体 |
| WO2017011767A2 (en) | 2015-07-15 | 2017-01-19 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3462257A (en) * | 1965-09-13 | 1969-08-19 | Scott & Sons Co O M | Turf management with azauracils plus fertilizer |
| US4013444A (en) * | 1973-02-12 | 1977-03-22 | Minnesota Mining And Manufacturing Company | Inhibiting grass growth with 5-acetamido-2,4-dimethyltrifluoromethanesulfonanilide |
| US4002628A (en) * | 1973-06-18 | 1977-01-11 | Eli Lilly And Company | Novel fluoroalkoxyphenyl-substituted nitrogen heterocycles |
| IE45765B1 (en) * | 1976-08-19 | 1982-11-17 | Ici Ltd | Triazoles and imidazoles useful as plant fungicides and growth regulating agents |
| US4584013A (en) * | 1983-05-18 | 1986-04-22 | Ciba-Geigy Corporation | Cyclohexanedionecarboxylic acid derivatives with herbicidal and plant growth regulating properties |
| US4704160A (en) * | 1984-04-02 | 1987-11-03 | The O. M. Scott & Sons Company | Combination fertilizer composition |
| US5123951A (en) * | 1986-03-31 | 1992-06-23 | Rhone-Poulenc Nederland B.V. | Synergistic plant growth regulator compositions |
| RU2126396C1 (ru) * | 1994-09-14 | 1999-02-20 | Сагами Кемикал Рисерч Сентр | Производные эпоксициклогексана и регуляторы роста растений |
| US5627134A (en) * | 1995-06-05 | 1997-05-06 | Basf Corporation | Plant growth regulating compositions and methods |
| DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| WO2000000203A1 (en) * | 1998-06-30 | 2000-01-06 | Eli Lilly And Company | Azepine derivatives having effects on serotonin related systems |
-
2001
- 2001-05-08 GB GBGB0111186.3A patent/GB0111186D0/en not_active Ceased
-
2002
- 2002-05-02 US US10/476,902 patent/US20040192671A1/en not_active Abandoned
- 2002-05-02 DE DE60203797T patent/DE60203797T2/de not_active Expired - Fee Related
- 2002-05-02 ES ES02750872T patent/ES2238583T3/es not_active Expired - Lifetime
- 2002-05-02 WO PCT/EP2002/004804 patent/WO2002089811A1/en not_active Ceased
- 2002-05-02 AT AT02750872T patent/ATE293448T1/de not_active IP Right Cessation
- 2002-05-02 JP JP2002586946A patent/JP2004532240A/ja active Pending
- 2002-05-02 EP EP02750872A patent/EP1392316B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532240A5 (enExample) | ||
| EP1392316B1 (en) | Benzo[d]azepine derivatives as 5-ht6 receptor antagonists. | |
| JP2003522101A5 (enExample) | ||
| AU2014294866B2 (en) | Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same | |
| JP2003532731A5 (enExample) | ||
| ZA200309005B (en) | New indole derivatives with 5-HT6 receptor affinity. | |
| JP2005527463A (ja) | Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン | |
| JP2004505078A5 (enExample) | ||
| JP2012510502A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| JP2002518502A5 (enExample) | ||
| JP2007520440A5 (enExample) | ||
| JP2005525332A5 (enExample) | ||
| CN1069643C (zh) | 抑制巨细胞病毒的二氮杂萘及其类似物 | |
| JP2002505286A5 (enExample) | ||
| JP2003503449A5 (enExample) | ||
| JP2005527542A5 (enExample) | ||
| JP2003502367A5 (enExample) | ||
| JP2005508969A5 (enExample) | ||
| JP2005533801A5 (enExample) | ||
| RU2005121125A (ru) | Аминоалкоксииндолы, как лиганды рецептора 5-нт6, для лечения заболеваний цнс | |
| JP2005527521A5 (enExample) | ||
| US6849644B2 (en) | Isoquinoline derivatives useful in the treatment of CNS disorders | |
| JP2006511498A5 (enExample) | ||
| CA2370830A1 (en) | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |